Temporal trends and regional disparities in costs and affordability of non-insulin antidiabetic drugs in China, 2015–2022: a retrospective observational study
- 1Department of Pharmacy Administration, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- 2Xi’an Aerospace Hospital, Xi’an, Shaanxi, China
Abstract
Objectives: To assess temporal trends and regional disparities in the costs and affordability of non-insulin antidiabetic drugs in China between 2015 and 2022.
Design: A retrospective observational study using monthly provincial procurement data.
Setting: 27 provincial-level administrative regions in mainland China from 2015 to 2022.
Participants: No individual participants were included. The units of analysis were aggregated monthly procurement records for 29 non-insulin antidiabetic drugs classified into nine therapeutic categories.
Primary and secondary outcome measures: The primary outcomes were the 30-day treatment cost and affordability ratio of non-insulin antidiabetic drugs at the national and regional levels. The 30-day treatment cost was calculated using defined daily doses and affordability was assessed as the ratio of the 30-day treatment cost to the corresponding minimum daily wage. Secondary outcomes included temporal changes in costs and affordability by therapeutic category, active ingredient and region.
Results: National average monthly costs fluctuated before 2019, reaching a peak of US$18.53 in 2019 and subsequently declined to US$11.34 in 2022. Costs declined across all therapeutic categories from 2019 to 2022, although the magnitude of reduction varied considerably. Affordability also improved over the study period, but substantial differences remained across therapeutic categories. By 2022, only biguanides and sulfonylureas had achieved good affordability at the category level, while several other categories remained above the affordability threshold. Regional disparities persisted throughout the study period; in 2022, affordability was relatively more favourable in the central region and poorer in the northwest, and no region achieved overall good affordability.
Conclusions: Between 2015 and 2022, the cost and affordability of non-insulin antidiabetic drugs in China improved overall, but disparities persisted across therapeutic categories and regions. These findings highlight the continuing challenge of ensuring equitable access to higher-cost therapies and provide a historical benchmark for evaluating subsequent changes in drug costs and affordability.
Related
- Regional disparities in hepatitis C treatment initiation and treatment delay in Saudi Arabia: a retrospective observational study
- Clinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study
- Temporal trends and disparities in mortality associated with heart failure and underlying ischemic heart disease in the US population : A Nationwide retrospective cross-sectional study (1999–2023)
- Temporal Distribution of Elevated-HbA1c Records and a Young-Adult Multiorgan Biomarker Profile in Diabetes: A Retrospective Observational Study.
- Temporal Trends and Demographic Disparities in Percutaneous Left Atrial Appendage Occlusion Utilization in the United States, 2016-2022
BibTeX
@article{liu2026temporal,
title = {{Temporal trends and regional disparities in costs and affordability of non-insulin antidiabetic drugs in China, 2015–2022: a retrospective observational study}},
author = {Xingchen Liu and Fengping Lei and Sundus Shukar and Xingyu Liu and Haoqi Wei and Chen Chen and Yu Fang and Caijun Yang},
journal = {BMJ Open},
year = {2026},
month = sep,
doi = {10.1136/bmjopen-2026-117523},
url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-117523},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Temporal trends and regional disparities in costs and affordability of non-insulin antidiabetic drugs in China, 2015–2022: a retrospective observational study
AU - Xingchen Liu
AU - Fengping Lei
AU - Sundus Shukar
AU - Xingyu Liu
AU - Haoqi Wei
AU - Chen Chen
AU - Yu Fang
AU - Caijun Yang
PY - 2026
DA - 2026/09/30
JO - BMJ Open
DO - 10.1136/bmjopen-2026-117523
UR - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-117523
AB - Objectives: To assess temporal trends and regional disparities in the costs and affordability of non-insulin antidiabetic drugs in China between 2015 and 2022. Design: A retrospective observational study using monthly provincial procurement data. Setting: 27 provincial-level administrative regions in mainland China from 2015 to 2022. Participants: No individual participants were included. The units of analysis were aggregated monthly procurement records for 29 non-insulin antidiabetic drugs classified into nine therapeutic categories. Primary and secondary outcome measures: The primary outcomes were the 30-day treatment cost and affordability ratio of non-insulin antidiabetic drugs at the national and regional levels. The 30-day treatment cost was calculated using defined daily doses and affordability was assessed as the ratio of the 30-day treatment cost to the corresponding minimum daily wage. Secondary outcomes included temporal changes in costs and affordability by therapeutic category, active ingredient and region. Results: National average monthly costs fluctuated before 2019, reaching a peak of US$18.53 in 2019 and subsequently declined to US$11.34 in 2022. Costs declined across all therapeutic categories from 2019 to 2022, although the magnitude of reduction varied considerably. Affordability also improved over the study period, but substantial differences remained across therapeutic categories. By 2022, only biguanides and sulfonylureas had achieved good affordability at the category level, while several other categories remained above the affordability threshold. Regional disparities persisted throughout the study period; in 2022, affordability was relatively more favourable in the central region and poorer in the northwest, and no region achieved overall good affordability. Conclusions: Between 2015 and 2022, the cost and affordability of non-insulin antidiabetic drugs in China improved overall, but disparities persisted across therapeutic categories and regions. These findings highlight the continuing challenge of ensuring equitable access to higher-cost therapies and provide a historical benchmark for evaluating subsequent changes in drug costs and affordability.
SN - 2044-6055
SN - 2044-6055
ER -